Premium
Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions
Author(s) -
ElSharkawy Nahla M.,
Radwan Wafaa M.,
Essa Enas S.,
Kandeel Eman Z.,
Abd ElFattah Eman K.,
Kandil Samia H.,
Kamel Azza M.
Publication year - 2017
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21378
Subject(s) - breast cancer , immunohistochemistry , flow cytometry , pathology , medicine , cancer , ctcf , biology , gene expression , immunology , gene , biochemistry , enhancer
Background BORIS, a paralog of the multifunctional CCCTC‐binding factor (CTCF) gene is restricted to testis and normally not present in females. It is aberrantly activated in various human cancers including cancer breast. Using immunohistochemistry, western blot and/or RT‐PCR, significantly higher levels of BORIS expression were reported in the neutrophils of cancer breast patients. We hypothesized that Flow Cytometry might be a better technique for objective quantitative evaluation of BORIS in neutrophils and we wanted to investigate if BORIS would discriminate between benign and malignant breast lesions. Methods The study included 85 females; 52 breast cancer, 13 benign breast lesions and 20 age‐matched healthy controls. BORIS expression in the neutrophils was detected by Flow Cytometry. Results High level of BORIS was detected in all malignant (64.4 ± 16.6%) and benign cases (67 ± 12.3), mean florescent intensity ratio (MFIR) of 7.2 ± 4.1 and 7 ± 3.5, median 5.8 and 6.6%; and staining index (SI) 8.3 ± 3.9 and 8.2 ± 3.4, median 7.6 and 7.9 respectively vs.13.4 ± 11.5% MFI 1.8 ± 0.7, median1.6 and SI 2.6 ± 0.69, median 2.5 for the control. BORIS level was comparable in the malignant and benign group ( P = 0.934) and significantly higher than control ( P = 0.0001). There was no correlation between neutrophil BORIS expression and ER/PR status, HER‐2/neu expression or tumor stage or size. Conclusions Increased BORIS expression in peripheral blood neutrophils is associated with both benign and malignant breast lesions; apparently, increased proliferation of breast tissue is the determining factor. This excludes BORIS as a tumor marker but it does not jeopardize its value as a potential therapeutic target. © 2016 International Clinical Cytometry Society